Artivion, Inc. announced that the FDA has approved the company’s AMDS hybrid prosthesis, an aortic arch remodeling device fo ...
(NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application ...
Artivion benefits from FDA premarket approval of AMDS, removing adoption barriers and unlocking a $150M U.S. TAM in acute ...
Artivion AORT recently secured FDA premarket approval (“PMA”) for its AMDS Hybrid Prosthesis to treat acute DeBakey Type I ...
US FDA grants premarket approval for Artivion’s AMDS Hybrid Prosthesis: Atlanta Artivion, Inc., a leading cardiac and vascular surgery c ...